AAP
MDGL icon

Arax Advisory Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Arax Advisory Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.3K Buy
+144
New +$73.8K ﹤0.01% 2924
2026
Q1 		– Sell
-27
Closed -$15.7K – 4122
2025
Q4 		$15.7K Buy
27
+12
+80% +$6.13K ﹤0.01% 2245
2025
Q3 		$6.88K Buy
+15
New +$5.6K ﹤0.01% 2759

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arax Advisory Partners's MDGL Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 144 shares worth $77.3K. The stake represents ﹤0.01% of the portfolio and ranks #2924 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MDGL as recently as Q4 2025.

Arax Advisory Partners first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Arax Advisory Partners held 144 shares of Madrigal Pharmaceuticals worth $77.3K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2924 holding.
  • Arax Advisory Partners first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.